March 27, 2017
AstraZeneca has obtained exclusive rights to develop and market Kyowa Hakko Kirin’s benralizumab for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD) in 13 Asian countries and regions. Kyowa Kirin said on March 24 that it has...read more